Iterum Therapeutics (ITRM) Competitors $1.77 +0.02 (+1.14%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ITRM vs. CRDF, CMPX, MGNX, ADCT, CADL, INZY, PRQR, CYBN, SLN, and ALECShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), MacroGenics (MGNX), ADC Therapeutics (ADCT), Candel Therapeutics (CADL), Inozyme Pharma (INZY), ProQR Therapeutics (PRQR), Cybin (CYBN), Silence Therapeutics (SLN), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Cardiff Oncology Compass Therapeutics MacroGenics ADC Therapeutics Candel Therapeutics Inozyme Pharma ProQR Therapeutics Cybin Silence Therapeutics Alector Iterum Therapeutics (NASDAQ:ITRM) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Which has more risk and volatility, ITRM or CRDF? Iterum Therapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Which has preferable earnings & valuation, ITRM or CRDF? Iterum Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$38.37M-$2.00-0.89Cardiff Oncology$688K316.61-$41.44M-$0.94-4.53 Does the MarketBeat Community believe in ITRM or CRDF? Iterum Therapeutics received 100 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 64.06% of users gave Cardiff Oncology an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Cardiff OncologyOutperform Votes4164.06% Underperform Votes2335.94% Do insiders and institutionals believe in ITRM or CRDF? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by company insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer ITRM or CRDF? Iterum Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 182.49%. Cardiff Oncology has a consensus target price of $10.33, indicating a potential upside of 142.57%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ITRM or CRDF more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Iterum Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -160.85% Cardiff Oncology -6,238.17%-73.97%-60.40% Does the media refer more to ITRM or CRDF? In the previous week, Cardiff Oncology had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for Cardiff Oncology and 0 mentions for Iterum Therapeutics. Cardiff Oncology's average media sentiment score of 0.49 beat Iterum Therapeutics' score of -0.75 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Overall Sentiment Iterum Therapeutics Negative Cardiff Oncology Neutral SummaryIterum Therapeutics and Cardiff Oncology tied by winning 8 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.70M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.8910.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-3.695.094.774.78Net Income-$38.37M$151.83M$120.15M$225.60M7 Day Performance-1.67%-2.13%-1.92%-1.23%1 Month Performance-0.28%-3.10%11.47%3.36%1 Year Performance9.26%11.54%30.54%16.60% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.0497 of 5 stars$1.77+1.1%$5.00+182.5%+6.0%$48.70MN/A-0.8910CRDFCardiff Oncology2.0224 of 5 stars$4.00+2.0%$10.33+158.3%+195.8%$204.52M$490,000.00-4.1720CMPXCompass Therapeutics2.6583 of 5 stars$1.47+0.7%$6.75+359.2%-13.2%$202.26M$850,000.00-4.0720MGNXMacroGenics3.5331 of 5 stars$3.20flat$7.63+138.3%-67.7%$200.84M$139.77M-2.03430ADCTADC Therapeutics3.0937 of 5 stars$2.06+9.0%$8.00+288.4%+51.9%$199.17M$70.72M-0.86310Gap UpCADLCandel Therapeutics2.9107 of 5 stars$6.13-9.2%$11.00+79.4%+681.3%$199.08M$120,000.00-3.6060Analyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumeINZYInozyme Pharma1.8652 of 5 stars$3.08+1.7%$17.00+451.9%-23.7%$197.86MN/A-2.0850PRQRProQR Therapeutics2.2298 of 5 stars$2.42-14.5%$7.60+214.0%+34.2%$197.67M$7.05M-8.13180Gap DownHigh Trading VolumeCYBNCybin1.5492 of 5 stars$9.83+0.5%$138.00+1,303.9%N/A$196.50MN/A-1.4950SLNSilence Therapeutics3.4418 of 5 stars$6.55+1.6%$57.20+773.3%-59.0%$196.04M$31.55M-4.11100ALECAlector4.2493 of 5 stars$1.99+1.0%$4.00+101.0%-76.4%$194.89M$61.51M-1.16270Analyst Downgrade Related Companies and Tools Related Companies Cardiff Oncology Alternatives Compass Therapeutics Alternatives MacroGenics Alternatives ADC Therapeutics Alternatives Candel Therapeutics Alternatives Inozyme Pharma Alternatives ProQR Therapeutics Alternatives Cybin Alternatives Silence Therapeutics Alternatives Alector Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITRM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts